REVIEW



Intravenous Parecoxib for Pain Relief after Orthopedic Surgery: A Systematic Review and Meta-analysis

Xiaofei Li \cdot Pengxiang Zhou \cdot Zhengqian Li \cdot Huilin Tang \cdot Suodi Zhai

Received: April 16, 2022 / Accepted: May 26, 2022 / Published online: June 15, 2022 \circledcirc The Author(s) 2022

ABSTRACT

Introduction: Orthopedic procedures have been associated with increased pain, making perioperative analgesia a major clinical concern. We assessed the efficacy and safety of intravenous parecoxib administration during the perioperative period for postoperative pain relief after orthopedic surgery in adults.

Xiaofei Li and Pengxiang Zhou contributed equally to this work.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40122-022-00400-1.

X. Li · P. Zhou · S. Zhai (⊠) Department of Pharmacy, Peking University Third Hospital, Beijing, China e-mail: zhaisuodi@163.com

X. Li

Department of Pharmacy, The Affiliated Hospital of Guizhou Medical University, Guiyang, China

P. Zhou · S. Zhai Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China

Z. Li

Department of Anesthesiology, Peking University Third Hospital, Beijing, China

H. Tang

Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA Methods: PubMed, Cochrane Library, EMBASE, and clinicaltrial.gov were searched from inception to 23 August 2021 without language restrictions. Randomized controlled trials comparing intravenous parecoxib with placebo or another active treatment for acute postoperative pain in adults after orthopedic surgery were included. The primary outcomes were the pain scores and cumulative morphine consumption. The secondary outcomes included the proportion of patients requiring rescue analgesics and the incidence of adverse events. The metaanalysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and was registered on the International Prospective Register of Systematic Reviews Registration (PROSPERO).

Results: Twenty-seven trials (n = 2840) from more than 20 countries involving six types of orthopedic surgery met the inclusion criteria. Compared with placebo, intravenous parecoxib administration led to reductions in postoperative resting pain scores at 6, 12, 24, and 48 h [mean difference (MD) -0.87, 95% confidence interval [CI] -1.71 to -0.03; MD -0.86, 95% CI -1.26 to -0.46; MD -0.57, 95% CI -0.84 to -0.31; MD -0.40, 95% CI -0.69 to -0.11, respectively], postoperative movement pain scores at 24 and 48 h (MD -0.66, 95% CI -1.14 to -0.19; MD -0.78, 95% CI -1.16 to -0.39, respectively), cumulative morphine consumption (MD -11.30 mg, 95% CI -14.79 to -7.81 mg), and the proportion of patients

Pain Ther (2022) 11:771-787

requiring rescue analgesia (relative risk 0.83, 95% CI 0.77–0.89). There was no difference in the incidence of adverse events between groups. *Conclusion*: Low to moderate evidence indicates that parecoxib might be an effective and safe analgesic in perioperative orthopedic settings. It relieves postoperative orthopedic pain while sparing opioid analgesic consumption without increasing the incidence of adverse events.

PROSPERO Registration: CRD42021274939.

Keywords: Morphine consumption; Orthopedic surgery; Pain score; Parecoxib; Perioperative analgesia

Key Summary Points

This review and meta-analysis assessed the efficacy and safety of intravenous parecoxib administration during the perioperative period for postoperative pain relief following orthopedic surgery in adults.

We included 27 randomized controlled trials comparing intravenous parecoxib with placebo or another active treatment.

Parecoxib relieves postoperative orthopedic pain while sparing opioid analgesic consumption without increasing the incidence of adverse events.

Parecoxib might be an efficacious and safe analgesic in perioperative orthopedic settings.

INTRODUCTION

Perioperative analgesia is often a major clinical concern for orthopedic surgeons. Increased pain has been related to orthopedic procedures such as lumbar spine surgery and joint replacement [1, 2]. Quality of life, function, and recovery time may be affected by suboptimal

perioperative pain relief [3]. Thus, multimodal analgesia and enhanced recovery are gaining attention, and their clinical applications are becoming more widespread [4]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are important components of multimodal analgesia [5]. Guidelines for the management of acute pain recommend multimodal analgesia, routinely including the administration of both an opioid and one or more non-opioid, and, frequently, an NSAID [6, 7].

In addition to relieving pain, perioperative NSAID administration has been shown to reduce patients' requirements for opioids without significant side effects [8, 9]. Selective cvclooxygenase (COX)-2 inhibitors administered via the enteral route (e.g., celecoxib) are effective in relieving mild to moderate pain. However, they are ineffective in cases of postoperative nausea and vomiting or when the oral route of administration is inaccessible. Therefore, appropriate NSAID use is of great importance, especially when patients are likely to be administered intravenous NSAIDs during the perioperative period. Parecoxib was the first parenterally administered COX-2 inhibitor approved in Europe and Asia for the treatment of postoperative pain [10]. According to a Cochrane systematic review of randomized controlled trials (RCTs) on postoperative pain control, a single dose of parecoxib provided effective analgesia compared with a placebo [11]. However, the aforementioned study did not differentiate between various types of surgery. While some studies have reported that parecoxib reduces opioid consumption and relieves pain [12, 13], in other trials, parecoxib administration did not reduce postoperative pain compared with placebo after knee and hip arthroplasty surgery [14, 15]. Although more studies have been published, the analgesic efficacy and safety of parecoxib use in orthopedic surgery remain unclear. Therefore, this systematic review and meta-analysis aimed to evaluate the benefits and risks of parecoxib use in orthopedic surgery.

METHODS

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [16] and Assessing the Methodological Quality of Systematic Reviews Guidelines [17]. The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42021274939). This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Eligibility Criteria and Outcome Definitions

Studies were selected on the basis of the following inclusion criteria: (1) RCTs comparing parecoxib injection with a placebo or other analgesics for pain relief; (2) having enrolled adults > 18 years of age undergoing orthopedic surgery; and (3) reporting data on postoperative pain score, cumulative analgesic consumption, proportion of patients requiring rescue analgesics, and incidence of adverse events. The exclusion criteria were as follows: (1) trials with no placebo or treatment group; (2) trials including participants with active gastrointestinal bleeding, ulceration, or severe liver dysfunction; and (3) abstracts, letters, editorials, conference articles, or duplicated studies. The primary outcomes included pain scores at different timepoints and cumulative morphine consumption (mg) over the first 24 h. Secondary outcomes included the proportion of patients requiring rescue analgesics and the incidence of adverse events.

We assessed clinical outcomes on the basis of the following predetermined definitions: (1) pain score reported using the visual analog scale (VAS: 0–10 cm, 0 = no pain and 10 = maximum pain; VAS: 0–100 mm, 0 = no pain and 100 = maximum pain) or verbal numerical rating scale (VNRS: 0–10, 0 = no pain and 10 = maximum pain); (2) cumulative morphine consumption (mg) in groups at 24 h postoperatively was recorded for each group to determine the effect of opioid-sparing, and other opioids were converted to intravenous morphine equivalents; (3) adverse events were recorded regardless of treatment or potential causal relationship with parecoxib.

Information Sources and Search Strategy

PubMed, Embase, Cochrane Library, and clinicaltrial.gov were searched from inception to 23 August 2021. There were no restrictions on specific language or year of publication. The following keywords were searched: "parecoxib," "orthopedic procedures," "perioperative period," "pain," "analgesia," "randomized controlled trial," and other related Medical Subject Headings terms or expressions. Additional searches were conducted by reviewing the reference lists of published articles. Details regarding the search strategy are presented in Table S1 (see the electronic supplementary material for details).

Study Selection and Data Extraction

After removing duplicates, screening for eligible articles (abstract and full text) was performed independently by two reviewers. Discrepancies were resolved by a third reviewer. Information on the first author, publication year, type of surgery, number of patients, interventions and controls, supplemental analgesics, and outcomes of interest was retrieved independently by two reviewers using a predesigned form. The agreement level of selections between two investigators was calculated by the kappa scores. A κ value of 0.81–1.00 indicated almost perfect agreement; 0.61-0.80 indicated substantial 0.21–0.60 indicated moderate agreement; agreement; and 0.20 indicated lower or slight agreement. Disagreement were resolved through discussion or by a third coordinator. The article authors were contacted for missing or incomplete data when necessary.

Quality Assessment

According to the Cochrane Risk of Bias tool, the risk of bias of each RCT was graded as low, high,

Data Synthesis and Analysis

Meta-analyses were performed using Review Manager version 5.4. (The Cochrane Collaboration, London, England). Opioids were converted to intravenous morphine equivalents according to Table S2 (see the electronic supplementary material for details). VAS 0–100 and VNRS 0–10, were converted to VAS 0–10. Median and interquartile range/range were converted to mean and standard deviation according to the Cochrane Handbook. Some trials had more than one intervention group. In these cases, we split the control group, according to the Cochrane Handbook.

Continuous variables are expressed as mean difference (MD) with 95% confidence intervals (CIs), and relative risk (RR) with 95% CI was calculated for dichotomous variables. Forest plots were used to summarize estimates and provide a comprehensive evaluation of the available evidence and pooled effect sizes from the meta-analyses. Heterogeneity across studies was evaluated using the chi-square (χ^2) test and I^2 index (P > 0.1) and $I^2 < 50\%$ indicated acceptable heterogeneity) [19, 20]. A randomeffect model was used for the meta-analyses [21]. Sensitivity analysis was performed by excluding high-risk bias studies or trials with different characteristics. Subgroup analyses were performed on the basis of orthopedic procedures. Funnel plots were constructed and tested for publication bias of outcome indicators when more than ten studies were included [22].

Grading the Evidence Strength

Two reviewers independently rated the certainty of the evidence for each outcome using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, which considers five factors: reporting bias, inconsistency, indirectness of evidence, imprecision, and other considerations such as publication bias [23]. Disagreements during the evaluation process were resolved by discussion or consultation with a third reviewer.

RESULTS

Search Results

The PRISMA flowchart is presented in Fig. 1. Database searches yielded a total of 916 citations, and a reference search identified one additional relevant abstract. A total of 329 duplicates were removed, and 264 abstracts were screened for orthopedic surgery. Finally, on the basis of the abstract, 49 were selected for full-text assessment, and 27 of these were included according to the inclusion and exclusion criteria. Perfect agreement was detected between the two reviewers during all steps of the review process and data extraction ($\kappa = 0.81-1.00$).

Characteristics of Included Studies

The characteristics of the included studies are presented in Table S3 (see the electronic supplementary material for details). A total of 27 RCTs with 2840 participants were included [14, 15, 24–48], with between 15 and 310 participants receiving intravenous parecoxib per study. There were 15 RCTs on knee and hip arthroplasty

[14, 15, 24–27, 29–31, 33, 36, 42, 46–48], 5 on lumbar spine surgery [32, 38, 40, 41, 44], 2 on anterior cruciate ligament reconstruction [34, 37], 2 on bunionectomy [39, 45], and 3 on other orthopedic surgery [28, 35, 43]. The control groups included placebo (23 trials), ketorolac (3 trials), paracetamol (3 trials), and celecoxib (1 trial). The included trials originated from China (7/27, 25.9%), the USA (5/27, 18.5%), Thailand (4/27, 14.8%), Germany (3/ 27, 11.1%), and other countries (Korea, Belgium, France, Germany, Sweden, Egypt, Czech Republic, and Cuba).



Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram







Fig. 3 Risk of bias summary

Risk of Bias Assessment

The risk of bias assessment for RCTs is summarized in Figs. 2 and 3. All studies were randomized; 23 trials were double-blind placebocontrolled, 22 described adequate random sequence generation processes, and 14 described allocation concealment methods. Therefore, 7 trials were evaluated as having low risk of bias, 11 trials were identified as having unclear risk of bias, and 9 trials as having high risk of bias.

Postoperative Pain Scores

The postoperative pain scores at different timepoints at rest and during movement are shown in Figs. 4 and 5. The results demonstrated that parecoxib could reduce the postoperative pain scores at rest compared with placebo at 6, 12, 24, and 48 h (MD -0.87, 95%) CI -1.71 to -0.03, P = 0.04; MD -0.86, 95% CI −1.26 to −0.46, *P* < 0.0001; MD −0.57, 95% CI −0.84 to −0.31, *P* < 0.0001; MD −0.40, 95% CI -0.69 to -0.11, P = 0.007; respectively). Parecoxib did not reduce the postoperative pain scores during movement at 6 and 12 h but could lower the postoperative movement pain scores at 24 and 48 h (MD -0.66, 95% CI -1.14 to -0.19, P = 0.006; MD -0.78, 95% CI -1.16to -0.39, P < 0.0001; respectively). In the subgroup analysis, compared with placebo, parecoxib was shown to reduce the resting pain scores at 24 h in lumbar spine surgery and hip arthroplasty (MD -0.79, 95% CI -1.32 to -0.26, P = 0.003; MD -0.44, 95% CI -0.66 to -0.22, P < 0.0001; respectively), although no difference in knee arthroplasty was detected (MD -0.47; 95% CI -1.02 to 0.08; P = 0.10; see Fig. S1 in the electronic supplementary material for details).

Cumulative Morphine Consumption over 24 h

TwelveRCTswereincluded[26, 28-30, 32, 33, 36, 38, 40, 42, 43, 46], with1135 patients in the parecoxib group and 920patients in the placebo group. The results

(a)									
	Pare	coxib		Co	ntrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD T	otal I	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bian 2018	3.37 2	2.33	46	3.49	1.76	42	17.7%	-0.12 [-0.98, 0.74]	
Martinez 2007 (post)	1.47	1.55	20	2.44	2.55	10	11.3%	-0.97 [-2.69, 0.75]	
Martinez 2007 (pre)	1.92 2	2.26	21	2.44	2.55	11	10.9%	-0.52 [-2.31, 1.27]	
Peng 2018	2.21 2	2.02	48	2.46	2.16	46	17.8%	-0.25 [-1.10, 0.60]	
Zhu 2014	1.19	0.5	50	3.28	0.5	50	21.4%	-2.09 [-2.29, -1.89]	*
Zhu 2016	2.5	0.8	60	3.4	1.2	62	20.9%	-0.90 [-1.26, -0.54]	-
			045			224	400.00/	0.07 [4.74 0.02]	
Hotorogonoity: Tou ² = 0	94. Chi2	- 60 6	245 0 df -	5 /D /	0 0000	221	- 02%	-0.07 [-1.71, -0.03]	
Test for overall effect: 7	= 2 03 /	= 00.0	9, ui – 1)	5 (F <	0.0000	JT), I [_] -	- 92 70		-4 -2 0 2 4
rest for overall effect. 2	- 2.00 (1	- 0.0							Favours Parecoxib Favours Control
(b)									
(d)	-								
Chudu an Cubanaun	Pa	recoxil	D	Maan	ontrol	Tetel	Mainht	Mean Difference	Mean Difference
Study or Subgroup		1.04	Total	Mean	1 40	Total	vveight	IV, Random, 95% CI	
lirarattananhachai 2008	3.23	1.91	40	3.5	1.40	42	12.2%	-0.27 [-0.96, 0.44]	
Mortinoz 2007 (post)	1 21	2 20	20	2 29	1.9	10	12.0%	1.40 [-2.00, -0.74]	
Martinez 2007 (post)	1.31	1.62	20	2.30	2	11	5.9%	-1.07 [-2.00, 0.02]	
Peng 2018	2.56	2 10	48	2.30	2 1 1	46	10.9%	0 13 [-2.49, 0.23]	
Xiao 2019	0.79	0.76	69	17	0.93	72	18.2%	-0.91 [-1.19 -0.63]	
Zhu 2014	1.38	0.67	50	2.84	0.37	50	18.9%	-1.46 [-1.67, -1.25]	+
Zhu 2016	2.4	1.1	60	3	0.9	62	17.2%	-0.60 [-0.96, -0.24]	
Total (95% CI)			375			353	100.0%	-0.86 [-1.26, -0.46]	
Heterogeneity: Tau ² = 0.2	20; Chi ² =	= 34.07	, df = 7	(P < 0.	0001);	l ² = 79	1%	-	-2 -1 0 1 2
Test for overall effect: Z =	= 4.26 (P	< 0.00	01)						Favours Parecoxib Favours Placebo
<i>′</i> .									
(c)									
	Pa	recoxi	b	C	ontro	I I		Mean Difference	Mean Difference
Study or Subgroup	Pa Mean	recoxi SD	b Total	C Mean	ontro SD	l Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Study or Subgroup Bian 2018	Pa <u>Mean</u> 2.89	recoxi SD 1.84	b <u>Total</u> 46	0 <u>Mean</u> 2.88	contro SD 1.65	l <u>Total</u> 42	Weight 8.1%	Mean Difference IV, Random, 95% CI 0.01 [-0.72, 0.74]	Mean Difference IV. Random, 95% Cl
<u>Study or Subgroup</u> Bian 2018 Jirarattanaphochai 2008	Pa <u>Mean</u> 2.89 2.6	recoxi SD 1.84 1.5	b <u>Total</u> 46 60	0 <u>Mean</u> 2.88 4	ontro SD 1.65 1.9	I <u>Total</u> 42 60	Weight 8.1% 9.9%	Mean Difference IV. Random. 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79]	Mean Difference IV. Random, 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post)	Pa <u>Mean</u> 2.89 2.6 1.08	recoxi SD 1.84 1.5 1.55	b <u>Total</u> 46 60 20	0 <u>Mean</u> 2.88 4 1.97	contro SD 1.65 1.9 2.89	I Total 42 60 10	Weight 8.1% 9.9% 1.7%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03]	Mean Difference IV. Random, 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre)	Pa <u>Mean</u> 2.89 2.6 1.08 1.53	recoxi SD 1.84 1.5 1.55 2.61	b <u>Total</u> 46 60 20 22	0 <u>Mean</u> 2.88 4 1.97 1.97	Contro SD 1.65 1.9 2.89 2.89	I Total 42 60 10 11	Weight 8.1% 9.9% 1.7% 1.6%	Mean Difference IV, Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5	recoxi SD 1.84 1.5 1.55 2.61 2.27	b Total 46 60 20 22 48	0 Mean 2.88 4 1.97 1.97 2.54	Contro SD 1.65 1.9 2.89 2.89 2.25	I Total 42 60 10 11 46	Weight 8.1% 9.9% 1.7% 1.6% 6.0%	Mean Difference IV, Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Diate 2008 (cost)	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3	recoxi SD 1.84 1.5 1.55 2.61 2.27 1.77	b Total 46 60 20 22 48 80	C Mean 2.88 4 1.97 1.97 2.54 3.29	Contro SD 1.65 1.9 2.89 2.89 2.25 1.96	I Total 42 60 10 11 46 26	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6%	Mean Difference IV. Random. 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.40 [-0.70, 021]	Mean Difference IV. Random, 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre) Riest 2008 (pre, post) Biot 2008 (pre)	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83	recoxi SD 1.84 1.5 1.55 2.61 2.27 1.77 1.52	b Total 46 60 20 22 48 80 80 80	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96	I Total 42 60 10 11 46 26 27 27	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6% 7.1%	Mean Difference IV. Random. 95% CI 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] 0.81 [45, 0.93]	Mean Difference IV. Random, 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre, post) Riest 2008 (pre) Yian 2019	Pa Mean 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.48	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.77 1.52 1.84 0.42	b Total 46 60 20 22 48 80 80 80 80	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89	I Total 42 60 10 11 46 26 27 27 27	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6% 7.1% 6.7% 18.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.9, -0.23]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.83 2.48 0.54	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58	b Total 46 60 20 22 48 80 80 80 80 69	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3	I Total 42 60 10 11 46 26 27 27 72	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6% 7.1% 6.7% 18.1% 19.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.49 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.41 [-1.09, -0.73]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016	Pa Mean 2.89 2.6 1.08 1.53 2.5 3 2.83 2.48 0.54 1.64 1.8	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8	b <u>Total</u> 46 60 20 22 48 80 80 80 80 69 50 60	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2	I Total 42 60 10 11 46 26 27 27 72 72 50 62	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.48 0.54 1.64 1.8	SD 1.84 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8	b Total 46 60 20 22 48 80 80 80 80 69 50 60	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2	I Total 42 60 10 11 46 26 27 27 72 50 62	Weight 8.1% 9.9% 1.7% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre) Riest 2008 (pre, post) Riest 2008 (pre, post) Riast 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI)	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.48 0.54 1.64 1.8	SD 1.84 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8	b Total 46 60 20 22 48 80 80 80 80 69 50 60 60	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2	I Total 42 60 10 11 46 26 27 27 72 50 62 433	Weight 8.1% 9.9% 1.7% 6.0% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.81 [-1.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.48 0.54 1.64 1.8	1.84 1.5 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8	b <u>Total</u> 46 60 20 22 48 80 80 80 80 69 50 60 615 , df = 1	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1	contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2	I Total 42 60 10 11 46 26 27 72 50 62 433 ; l ² = 6 ²	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.48 0.54 1.64 1.8 09; Chi ² =	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8 = 25.90 < 0.00	b <u>Total</u> 46 60 20 22 48 80 80 80 80 69 50 60 615 1, df = 1 01)	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1	contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2	I Total 42 60 10 11 46 26 27 72 50 62 433 ; ² = 6 ⁻¹	Weight 8.1% 9.9% 1.6% 6.0% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 2.83 2.48 0.54 1.64 1.8	SD 1.84 1.5 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8 = 25.900 < 0.000	b Total 46 60 20 22 48 80 80 80 80 69 50 60 615 9, df = 1 01)	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.004)	I Total 42 60 10 11 46 26 27 72 50 62 433 ; ² = 6 ⁻¹	Weight 8.1% 9.9% 1.6% 6.0% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.49 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% Cl) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 0.54 1.64 1.8 0.54 1.64 1.8	SD 1.84 1.5 2.61 2.27 1.77 1.52 1.84 0.42 0.42 0.8 = 25.90 < 0.00	b Total 46 60 20 22 48 80 80 80 69 50 60 615 1, df = 1 01)	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.004)	l Total 42 60 10 11 46 26 27 72 50 62 433 ; ² = 6 ⁻¹	Weight 8.1% 9.9% 1.7% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.49 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d)	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.83 0.54 1.64 1.64 1.8 0.9; Chi ² =	1.84 1.55 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8 = 25.90 < 0.00	b <u>Total</u> 46 60 20 22 48 80 80 80 80 80 69 950 60 615 50 60 615 101 01)	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.004)	 	Weight 8.1% 9.9% 1.7% 1.6% 6.0% 6.6% 7.1% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% CI 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference	Mean Difference IV. Random, 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup	Pa Mean 2.89 2.6 1.08 1.53 2.5 3 2.83 2.48 0.54 1.64 1.8 09; Chi ² = = 4.23 (P Pa Mean	recoxi <u>SD</u> 1.84 1.5 2.61 1.55 2.61 1.55 2.61 1.55 2.61 1.52 1.84 0.42 0.58 0.8 = 25.90 < 0.00 recoxi <u>SD</u>	b <u>Total</u> 46 60 20 22 48 80 80 80 80 80 80 80 69 50 60 615 615 615 701)	C Mean 2.88 4 1.97 7.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.004)	$ \frac{1}{10000000000000000000000000000000000$	Weightt 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.48 0.54 1.64 1.8 09; Chi ² = 4.23 (P Pa <u>Mean</u> 1.89	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 2.27 1.77 1.52 0.58 0.8 = 25.90 < 0.00 recoxi <u>SD</u> 1.54	b <u>Total</u> 46 60 20 22 48 80 80 80 80 80 80 80 60 615 615 615 615 701 81 61 61 61 61 61 61 61 61 61 6	C Mean 2.88 4 1.97 2.54 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.004)	$ \frac{1}{10000000000000000000000000000000000$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.44 [-2.47, 1.59] -0.44 [-2.47, 1.59] -0.44 [-2.47, 1.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008	Pa <u>Mean</u> 2.89 2.6 1.08 1.53 2.5 3 2.83 2.48 0.54 1.64 1.8 09; Chi ² = 4.23 (P Pa <u>Mean</u> 1.59	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8 = 25.90 < 0.00 recoxi <u>SD</u> 1.54 1.2	b <u>Total</u> 46 60 20 22 48 80 80 80 80 60 615 (, df = 1 01) b <u>Total</u> 46 60 60 61 5 60 60 60 60 60 60 60 60 60 60	C Mean 2.88 4 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32 2.7	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.004) Contro SD 1.7 1.6	$ \frac{1}{10000000000000000000000000000000000$	Weight 8.1% 9.9% 1.6% 6.0% 6.7% 18.1% 19.1% 15.1% 100.0% 1% 10.4% 14.0%	Mean Difference IV. Random, 95% CI 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% CI -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre, post) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018	Pa Mean 2.89 2.66 1.08 1.53 2.53 3 2.83 2.48 0.54 1.64 1.89 0.9; Chi ² = 4.23 (P Pa Mean 1.89 1.55 2.04	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.52 2.61 2.27 1.52 1.84 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 0.42 1.55	b <u>Total</u> 46 60 20 22 48 80 80 69 50 615 50 615 (, df = 1 01) b <u>Total</u> 46 60 48 80 80 80 80 60 80 80 80 80 80 80 80 80 80 8	C Mean 2.888 4 1.97 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32 2.7 2.2	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.004)	$ \frac{1}{10000000000000000000000000000000000$	Weightt 8.1% 9.9% 1.6% 6.6% 7.1% 6.6% 7.1% 101.0% 100.0% 1% 100.0% 1% 100.0% 9.7%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.49 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.16 [-0.88, 0.56]	Mean Difference IV. Random, 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019	Pa Mean 2.89 2.6.1 1.08 1.53 2.5.2 2.83 2.48 0.54 1.64 1.88 0.90; Chi ² + Pa Mean 1.89 1.52 2.04 0.11	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.52 0.42 0.58 0.42 0.58 0.42 0.58 0.42 0.58 0.42 1.57 1.52 1.64 1.52 1.64 1.52 1.64 1.52 1.64 1.52 1.64 1.52 1.64 1.52 1.54 1.55	b <u>Total</u> 46 60 20 22 48 80 80 80 80 80 80 80 69 50 60 615 50 60 615 50 60 60 60 60 60 60 60 60 60 6	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32 2.7 7 2.2 2.7 2.2 0.23	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.004) Contro SD 1.7 1.6 1.66 0.5	$ \frac{1}{10000000000000000000000000000000000$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0% 1% Weight 10.4% 14.0% 9.7% 23.1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.40 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.16 [-0.88, 0.56] -0.12 [-0.26, 0.02]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014	Pa Mean 2.899 2.6.1.08 1.08 1.53 2.5.5 3 2.83 2.83 2.83 2.83 2.84 0.54 1.64 1.89 0.9; Chi ² = 4.23 (P Pa Mean 1.89 1.5 2.044 0.11 1.67	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.52 2.61 2.27 1.52 1.52 2.61 2.27 1.52 2.61 2.27 1.52 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 2.27 1.55 2.61 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 2.51 1.52 1.52 1.52 1.52 1.52 1.52 1.52 1.52 1.54 1.54 1.54 1.9 1.9 3.90 0.36 0.03 0.03 1.54	b <u>Total</u> 46 600 202 22 48 800 800 800 800 800 800 800	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32 2.7 2.2 2.7 2.2 2.0.23 2.22	Contro SD 1.65 1.99 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.004) Contro SD 1.7 1.6 1.66 0.5 0.5 0.5	$ \frac{1}{10000000000000000000000000000000000$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0% 1%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.49 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.12 [-0.26, 0.02] -0.55 [-0.73, -0.37]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014	Pa Mean 2.899 2.6.6 1.08 1.53 2.5.5 3 2.833 2.484 0.544 1.64 1.89 0.97 Chi² + 3.33 Paa Mean 1.89 1.5 2.044 0.11 1.67 1.67	recoxi <u>SD</u> 1.84 1.55 2.61 2.27 1.77 1.52 1.84 0.42 0.58 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.	b <u>Total</u> 46 600 202 22 48 800 800 609 500 6015 6015 601 615 7011 60 46 600 48 600 48 600 600 601 600 600 600 600 600	C Mean 2.88 4 4 3.29 3.29 3.29 2.55 2.1 0 (P = 1 C C Mean 2.32 2.7 2.55 2.1 0 (P = 1 2.55 2.1 1 0 (P = 1 2.55 2.1 1 0 (P = 1 2.55 2.1 1 0 (P = 1) 2.52 2.1 1 0 (P = 1) 2.55 2.1 1 0 (P = 1) 2.55 2.1 2.1 1 0 (P = 1) 2.55 2.1 1 0 (P = 1) 2.55 2.1 1 0 (P = 1) 2.55 2.1 2.1 1 0 (P = 1) 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.55 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 0.89 0.3 1.2 0.0004) 0.30 1.2 0.0004)	$ \frac{1}{2}$ $\frac{1}{2}$ $$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0% 1% Weight 10.4% 14.0% 9.7% 23.1% 22.3% 20.6%	Mean Difference IV. Random, 95% CI 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.08 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.46 [-1.27, 0.35] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.16 [-0.88, 0.56] -0.12 [-0.26, 0.02] -0.55 [-0.73, -0.37] -0.10 [-0.35, 0.15]	Mean Difference IV. Random. 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Xiao 2019 Zhu 2016 Zhu 2018 Xiao 2019 Zhu 2016 Total (95% CI)	Pa Mean 2.89 2.6. 1.08 1.53 2.63 2.63 2.63 2.64 1.64 1.8 0.9; Chi ² : 4.23 (P Pa 1.64 1.69 1.52 2.04 0.11 1.67 1	recoxi <u>SD</u> 1.84 1.5 2.61 1.52 2.61 2.27 1.77 1.77 1.72 1.84 0.42 0.58 0.8 = 25.900 sD 1.54 1.2 1.9 0.36 0.43 0.8 0.8	b <u>Total</u> 46 600 202 22 48 800 800 800 800 600 615 5 615 5 010 1 010 1 010 2 2 2 48 800 800 800 800 800 800 800	C Mean 2.88 4 1.97 1.97 2.54 3.29 3.29 3.29 3.29 2.55 2.1 0 (P = 1 C C Mean 2.32 2.7 2.2 0.23 2.22 1.1	Contro SD 1.65 1.9 2.89 2.25 1.96 0.89 0.3 1.9 0.004) 1.9 0.004) 1.9 0.004) 1.9 0.004) 1.7 1.6 0.5 0.5 0.5 0.6	$ \frac{1}{10000000000000000000000000000000000$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 6.6% 15.1% 15.1% 100.0% 1% Weight 10.0% 23.1% 22.3% 20.6% 100.0%	Mean Difference IV. Random, 95% CI 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.95, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.91 [-1.09, -0.73] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% CI -0.43 [-1.71, -0.69] -0.16 [-0.88, 0.56] -0.15 [-0.73, -0.37] -0.50 [-0.73, -0.37] -0.10 [-0.35, 0.15] -0.44 [-0.43 [-0.44] -0.45 [-0.73, -0.37] -0.44 [-0.44] -0.45 [-0.73, -0.37] -0.44 [-0.44] -0.44 [-0.44] -0.45 [-0.73, -0.37] -0.44 [-0.44] -0.45 [-0.73, -0.37] -0.44 [-0.44] -0.44 [-0.44] -0.45 [-0.44] -0.45 [-0.44] -0.44 [-0.44]	Mean Difference IV. Random, 95% CI
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre, post) Xiao 2019 Zhu 2014 Zhu 2014 Total (95% CI) Heterogeneity: Tau² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Xiao 2019 Zhu 2014 Zhu 2018 Xiao 2019 Zhu 2014 Zhu 2014 Zhu 2014 Zhu 2014 Zhu 2014 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau² = 0.0	Pa Mean 2.89 2.6. 1.08 1.53 2.5. 3 2.83 2.48 0.54 1.64 1.8 0.9; Chi ² 4.23 (P Pa Mean 1.89; Solid 2.04 0.11 1.67 1 N9; Chi ² 4.23 (P	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 2.27 1.52 2.87 1.77 1.52 1.84 0.42	b Total 46 600 20 22 48 800 800 800 800 800 800 800	C Mean 2.88 4 4 1.97 2.54 3.29 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C C Mean 2.32 2.7 2.2 0.23 2.22 1.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.0004) 0.0004)	$ \frac{\text{Total}}{2} + \frac{1}{2} + \frac{1}{$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 18.1% 19.1% 15.1% 100.0% 1% Weight 10.4% 23.1% 22.3% 20.6% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.35] -0.81 [-1.65, 0.03] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.16 [-0.88, 0.56] -0.12 [-0.26, 0.02] -0.55 [-0.73, -0.37] -0.10 [-0.35, 0.15] -0.40 [-0.69, -0.11]	Mean Difference IV. Random. 95% Cl
Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Martinez 2007 (post) Martinez 2007 (pre) Peng 2018 Riest 2008 (pre, post) Riest 2008 (pre, post) Riest 2008 (pre) Xiao 2019 Zhu 2014 Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014 Jua 2018 Viao 2019 Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014 Zhu 2014 Zhu 2016 Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	Pa Mean 2.899 2.6: 1.08 1.53 2.55 3 2.68 3 2.248 0.54 1.64 1.84 0.54 1.64 1.84 0.99; Chi ² : 4.23 (P Pa Mean 1.99; Chi ² : 2.04 0.11 1.67 1 9.20 0.11 1.67 2.04 0.11 1.67 2.04 0.11 1.67 2.04 0.11 1.67 2.04 0.11 1.67 2.04 0.11 1.67 2.04 0.11 1.67 2.05 1.08 1.64 1.64 1.64 1.64 1.64 1.64 1.64 1.64	recoxi <u>SD</u> 1.84 1.5 1.55 2.61 1.77 1.52 2.77 1.72 1.77 1.52 1.84 0.42 0.58 0.8 • • • • • • • • • • • • •	b Total 46 60 20 22 48 80 80 80 80 80 80 80 80 60 615 50 60 50 60 80 60 50 60 60 60 80 80 80 80 80 80 80 80 80 8	C Mean 2.88 4 4 1.97 2.54 3.29 3.29 3.29 1 2.55 2.1 0 (P = 1 C Mean 2.32 2.7 2.2 0.23 2.22 1.1	Contro SD 1.65 1.9 2.89 2.25 1.96 1.96 1.96 0.89 0.3 1.2 0.0004) Contro SD 1.7 1.6 1.66 0.5 0.5 0.6	$ \frac{\text{Total}}{2} + \frac{1}{2} + \frac{1}{$	Weight 8.1% 9.9% 1.7% 1.6% 6.6% 7.1% 6.7% 19.1% 15.1% 100.0% 1% Weight 10.4% 14.0% 9.7% 23.1% 22.3% 20.6% 100.0%	Mean Difference IV. Random, 95% Cl 0.01 [-0.72, 0.74] -1.40 [-2.01, -0.79] -0.89 [-2.81, 1.03] -0.44 [-2.47, 1.59] -0.04 [-0.55, 0.87] -0.29 [-1.14, 0.56] -0.46 [-1.27, 0.36] -0.46 [-1.27, 0.36] -0.46 [-0.69, -0.23] -0.46 [-0.69, -0.23] -0.30 [-0.66, 0.06] -0.57 [-0.84, -0.31] Mean Difference IV. Random, 95% Cl -0.43 [-1.11, 0.25] -1.20 [-1.71, -0.69] -0.16 [-0.88, 0.56] -0.12 [-0.26, 0.02] -0.55 [-0.73, -0.37] -0.10 [-0.35, 0.15] -0.40 [-0.69, -0.11]	Mean Difference IV. Random. 95% Cl

Fig. 4 Forest plot of pain scores at rest between the parecoxib and placebo groups at a 6 h, b 12 h, c 24 h, d 48 h after surgery

showed that, compared with placebo, parecoxib could reduce cumulative morphine consumption over 24 h (MD -11.30 mg, 95% CI -14.79 to -7.81; P < 0.00001). Subgroup analyses revealed significant reductions in cumulative morphine consumption with parecoxib in knee

arthroplasty, hip arthroplasty, and other orthopedic procedures (MD -16.19 mg, 95% CI -19.12 to -13.26, *P* < 0.00001; MD -9.28 mg, 95% CI -14.87 to -3.70, *P* = 0.001; MD -11.07 mg, 95% CI -16.81 to -5.33,

(a)									
(4)	Par	ecoxił		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
Bian 2018	5.62	2.31	46	5.8	2.41	42	19.2%	-0.18[-1.17, 0.81]	
Ittichaikulthol 2010	4.39	1.9	40	7 57	1.93	40	19.8%	-3 18 [-4 02 -2 34]	
Martinez 2007 (post)	3.86	3.27	20	4.32	4.03	10	10.7%	-0.46 [-3.34, 2.42]	
Martinez 2007 (pre)	3.75	3.86	22	4.32	4.03	11	10.7%	-0.57 [-3.45, 2.31]	
Peng 2018	3.54	17	48	3.65	1.91	46	20.2%	-0 11 [-0 84 0 62]	
Siribumrungwong 2015	6	1.53	32	5.8	2 25	32	19.4%	0 20 [-0 74 1 14]	
on building ang 2010		1.00	02	0.0	2.20	02	10.170	0.20[0.14, 1.14]	
Total (95% CI)			208			181	100.0%	-0.76 [-2.09, 0.57]	
Heterogeneity: Tau ² = 2.1	13; Chi² =	= 40.17	, df = 5	(P < 0.	00001); ² = 8	88%	-	
Test for overall effect: Z =	= 1.12 (P	= 0.26	5)						-4 -2 U 2 4 Eavours Parecovib Eavours Control
(b)	_								
Study or Subaroun	Par	recoxi	b Totol	C	ontrol	Total	Moight	Mean Difference	Mean Difference
Bion 2018	F 70	4 74	TOLAL	wean	1 04	10121	12 00/	0.24 [0.05 0.52]	
Didi12010	0.79	1./1	40	0	1.01	42	13.9%	-U.ZI [-U.95, U.53]	-
literationenheahei 2000	3.52	1.//	40	4.89	1.10	40	12.0%	-1.37 [-2.03, -0.71]	
Martinez 2007 (nost)	4.8	1.9	00	5.8	2.1	10	13.9%	-1.00 [-1.72, -0.28]	
Martinez 2007 (post)	3.65	2.81	20	4.54	3.14	10	8.3%	-0.89 [-3.19, 1.41]	
Martinez 2007 (pre)	2.94	3.38	22	4.54	3.14	11	8.2%	-1.60 [-3.93, 0.73]	
Peng 2018	3.42	1.6	48	3.85	1.69	46	14.1%	-0.43 [-1.10, 0.24]	-
Siribumrungwong 2015	5.6	1.84	32	4.8	2.4	32	12.9%	0.80 [-0.25, 1.85]	-
XIao 2019	3.57	0.96	69	6.31	1.1	72	14.8%	-2.74 [-3.08, -2.40]	-
Total (95% CI)			337			313	100.0%	-0.93 [-1.91, 0.06]	•
Heterogeneity: Tau ² = 1.6	38; Chi ² =	92.20	, df = 7	(P < 0.	00001); l ² = 9	2%		
Test for overall effect: Z =	= 1.85 (P	= 0.06)						-4 -2 U 2 4
									Favours Farecoxid Favours Control
(c)									
(0)	Par	recoxi	b	С	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Bian 2018	5.64	1.68	46	5.54	1.75	42	12.5%	0.10 [-0.62, 0.82]	
Ittichaikulthol 2010	2.96	1.4	40	3.31	1.4	40	13.5%	-0.35 [-0.96, 0.26]	
Jirarattanaphochai 2008	4.3	1.8	60	5.7	2.1	60	12.7%	-1.40 [-2.10, -0.70]	
Martinez 2007 (post)	2.4	2.81	20	4.65	3.77	10	2.7%	-2.25 [-4.89, 0.39]	
Martinez 2007 (pre)	3.28	3.22	22	4.65	3.77	11	2.8%	-1.37 [-3.97, 1.23]	
Peng 2018	3.58	1.7	48	3.87	1.88	46	12.4%	-0.29 [-1.02, 0.44]	
Siribumrungwong 2015	5	1.99	32	1 2	1 97				
Xiao 2019			02	4.5		32	10.1%	0.70 [-0.27, 1.67]	+
	3.25	0.93	69	4.87	1.12	32 72	10.1% 16.1%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28]	+ +-
Zhu 2014	3.25 2.02	0.93 0.34	69 50	4.3 4.87 2.76	1.12 0.43	32 72 50	10.1% 16.1% 17.2%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59]	
Zhu 2014	3.25 2.02	0.93 0.34	69 50	4.87 2.76	1.12 0.43	32 72 50	10.1% 16.1% 17.2%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59]	- ,
Zhu 2014 Total (95% CI)	3.25 2.02	0.93	69 50 387	4.3 4.87 2.76	1.12 0.43	32 72 50 363	10.1% 16.1% 17.2% 100.0%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	- , →
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3	3.25 2.02 33; Chi² =	0.93 0.34 46.37	69 50 387 (, df = 8	4.3 4.87 2.76	1.12 0.43 00001	32 72 50 363); I ² = 8	10.1% 16.1% 17.2% 100.0% 3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z =	3.25 2.02 33; Chi² = = 2.75 (P	0.93 0.34 : 46.37 = 0.00	69 50 387 7, df = 8	4.3 4.87 2.76 (P < 0.	1.12 0.43	32 72 50 363); ² = 8	10.1% 16.1% 17.2% 100.0% 3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	-4 -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z =	3.25 2.02 33; Chi² = = 2.75 (P	0.93 0.34 : 46.37 = 0.00	69 50 387 7, df = 8	4.3 4.87 2.76 (P < 0.	1.12 0.43	32 72 50 363); I ² = 8	10.1% 16.1% 17.2% 100.0% 3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	
Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d)	3.25 2.02 33; Chi² = = 2.75 (P	0.93 0.34 : 46.37 = 0.00	69 50 387 7, df = 8 6)	4.3 4.87 2.76	1.12 0.43	32 72 50 363); ² = 8	10.1% 16.1% 17.2% 100.0% 3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	
Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d)	3.25 2.02 33; Chi ² = = 2.75 (P Par	0.93 0.34 : 46.37 = 0.00	69 50 387 7, df = 8 6) b	4.3 4.87 2.76 (P < 0.	1.12 0.43 00001	32 72 50 363); I ² = 8	10.1% 16.1% 17.2% 100.0% 3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19]	4 -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup	3.25 2.02 33; Chi ² = = 2.75 (P Par <u>Mean</u>	0.93 0.34 : 46.37 = 0.00 recoxi SD	69 50 387 7, df = 8 6) b <u>Total</u>	4.3 4.87 2.76 (P < 0.	1.12 0.43 000001 ontrol	32 72 50 363); I ² = 8 <u>Total</u>	10.1% 16.1% 17.2% 100.0% 3% Weight	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] 	-4 -2 0 2 4 Favours Parecoxib Favours Control Mean Difference IV. Random, 95% Cl
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) <u>Study or Subgroup</u> Bian 2018	3.25 2.02 33; Chi ² = = 2.75 (P Par <u>Mean</u> 4.86	0.93 0.34 : 46.37 = 0.00 recoxi <u>SD</u> 1.55	69 50 387 7, df = 8 6) b <u>Total</u> 46	4.3 4.87 2.76 (P < 0. C <u>Mean</u> 4.88	1.12 0.43 000001 ontrol <u>SD</u> 1.58	32 72 50 363); I ² = 8 <u>Total</u> 42	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19]	A -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) <u>Study or Subgroup</u> Bian 2018 Jirarattanaphochai 2008	3.25 2.02 33; Chi ² = = 2.75 (P <u>Par</u> <u>Mean</u> 4.86 3.1	0.93 0.34 : 46.37 = 0.00 recoxii <u>SD</u> 1.55 1.4	69 50 387 (, df = 8 6) b <u>Total</u> 46 60	4.3 4.87 2.76 (P < 0. (P < 0. <u>Mean</u> 4.88 4.3	1.12 0.43 000001 000001 000001 <u>SD</u> 1.58 1.6	32 72 50 363); l ² = 8 <u>Total</u> 42 60	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66]	A -2 0 2 4 Favours Parecoxib Favours Control Mean Difference IV. Random. 95% Cl
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.; Test for overall effect: Z = (d) <u>Study or Subgroup</u> Bian 2018 Jirarattanaphochai 2008 Peng 2018	3.25 2.02 33; Chi ² = = 2.75 (P <u>Pan</u> 4.86 3.1 3.42	0.93 0.34 : 46.37 = 0.00 recoxi <u>SD</u> 1.55 1.4 1.82	69 50 387 (, df = 8 6) b <u>Total</u> 46 60 48	4.3 4.87 2.76 (P < 0. C <u>Mean</u> 4.88 4.3 3.83	1.12 0.43 000001 000001 1.58 1.6 1.94	32 72 50 363); l ² = 8 <u>Total</u> 42 60 46	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6% 13.7%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.06 [-1.74, -0.68] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35]	A -2 0 2 4 Favours Parecoxib Favours Control Mean Difference IV. Random. 95% Cl
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019	3.25 2.02 33; Chi ² = = 2.75 (P <u>Par</u> 4.86 3.1 3.42 2.54	0.93 0.34 : 46.37 = 0.00 recoxi <u>SD</u> 1.55 1.4 1.82 0.9	69 50 387 , df = 8 6) b <u>Total</u> 46 60 48 69	4.3 4.87 2.76 (P < 0. C <u>Mean</u> 4.88 4.3 3.83 3.79	0.43 0.43 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001 000001	32 72 50 363); l ² = 8 <u>Total</u> 42 60 46 72	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6% 13.7% 24.3%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35] -1.25 [-1.57, -0.93]	-4 -2 0 2 4 Favours Parecoxib Favours Control Mean Difference IV. Random. 95% Cl
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014	3.25 2.02 33; Chi² = = 2.75 (P <u>Par</u> 4.86 3.1 3.42 2.54 1.91	0.93 0.34 : 46.37 = 0.00 recoxii <u>SD</u> 1.55 1.4 1.82 0.9 0.3	69 50 387 7, df = 8 6) b Total 46 60 48 69 50	4.3 4.87 2.76 (P < 0. (P < 0. <u>Mean</u> 4.88 4.3 3.83 3.79 2.6	0.43 0.43 000001 000001 000001 000001 000001 1.58 1.6 1.94 1.03 0.53	32 72 50 363); I ² = 8 <u>Total</u> 42 60 46 72 50	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6% 13.7% 24.3% 27.5%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.066 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35] -1.25 [-1.57, -0.93] -0.69 [-0.86, -0.52]	A -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014 Total (95% CI)	3.25 2.02 33; Chi ² = = 2.75 (P <u>Pan</u> 4.86 3.1 3.42 2.54 1.91	0.93 0.34 = 46.37 = 0.00 recoxi <u>SD</u> 1.55 1.4 1.82 0.9 0.3	69 50 387 5, df = 8 6) b Total 46 60 48 69 50 273	4.3 4.87 2.76 (P < 0. (P < 0. <u>Mean</u> 4.88 4.3 3.83 3.79 2.6	1.12 0.43 000001 000001 1.58 1.6 1.94 1.03 0.53	32 72 50 363); l ² = 8 <u>Total</u> 42 60 46 72 50 270	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6% 13.7% 24.3% 27.5% 100.0%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35] -1.25 [-1.57, -0.93] -0.69 [-0.86, -0.52] -0.78 [-1.16, -0.39]	A -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014 Total (95% Cl) Heterogeneity: Tau ² = 0.4	3.25 2.02 33; Chi ² = = 2.75 (P Par 4.86 3.1 3.42 2.54 1.91	0.93 0.34 = 46.37 = 0.00 recoxi <u>SD</u> 1.55 1.4 1.82 0.9 0.3	69 50 387 5, df = 8 6) b Total 46 60 48 69 50 273	4.3 4.87 2.76 (P < 0. (P < 0. Mean 4.88 4.3 3.83 3.79 2.6 (P = 0	000001 000001 000001 000001 000001 00001 0001 0001 0001 0001 0001 0001 00001 00001 000000 000000 000000 000000 000000	32 72 50 363); I ² = 8 <u>Total</u> 42 60 46 72 50 270 270	10.1% 16.1% 17.2% 100.0% 3% Weight 15.9% 18.6% 13.7% 24.3% 27.5%	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35] -1.25 [-1.57, -0.93] -0.69 [-0.86, -0.52] -0.78 [-1.16, -0.39]	A -2 0 2 4 Favours Parecoxib Favours Control
Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.3 Test for overall effect: Z = (d) Study or Subgroup Bian 2018 Jirarattanaphochai 2008 Peng 2018 Xiao 2019 Zhu 2014 Total (95% CI) Heterogeneity: Tau ² = 0.1 Test for overall effect: Z =	3.25 2.02 33; Chi ² = = 2.75 (P Par 4.86 3.1 3.42 2.54 1.91 13; Chi ² = = 3.92 (P	0.93 0.34 = 46.37 = 0.00 recoxi <u>SD</u> 1.55 1.4 1.82 0.9 0.3	b Total 6 7 7 7 6 7 7 7 7 7 7 7 7	4.3 4.87 2.76 (P < 0. (P < 0. <u>Mean</u> 4.3 3.83 3.79 2.6 (P = 0.	000001 000001 000001 000001 000001 00001 00001 00001 00001 00001 00001 00001 000001 000001 000001 000001 00000000	32 72 50 363); I ² = 8 <u>Total</u> 42 60 46 72 50 270 ² = 78%	10.1% 16.1% 17.2% 100.0% 3% <u>Weight</u> 15.9% 18.6% 13.7% 24.3% 27.5% 100.0% 6	0.70 [-0.27, 1.67] -1.62 [-1.96, -1.28] -0.74 [-0.89, -0.59] -0.66 [-1.14, -0.19] -0.66 [-1.14, -0.19] -0.02 [-0.67, 0.63] -1.20 [-1.74, -0.66] -0.41 [-1.17, 0.35] -1.25 [-1.57, -0.93] -0.69 [-0.86, -0.52] -0.78 [-1.16, -0.39]	Mean Difference IV. Random, 95% Cl

Fig. 5 Forest plot of pain scores during movement between the parecoxib and placebo groups at a 6 h, b 12 h, c 24 h, d 48 h after surgery

P = 0.0002; Fig. 6), but there was no difference between comparators in lumbar surgery.

Proportion of Patients Requiring Rescue Analgesia

Pooled data from five RCTs (548 participants) [14, 39, 45, 47, 48] showed that parecoxib use

resulted in significant reduction in the proportion of patients requiring rescue analgesia compared with placebo (RR 0.83, 95% CI 0.77–0.89, P < 0.00001, Fig. 7).

	Pa	recoxib)	c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.9.1 lumbar									
Jirarattanaphochai 2008	28	14.1	60	45.2	21	60	7.0%	-17.20 [-23.60, -10.80]	
Riest 2008 (post)	30.1	23.6	80	31.3	21.8	26	5.3%	-1.20 [-11.05, 8.65]	
Riest 2008 (pre,post)	22.8	19.2	80	31.3	21.8	27	5.6%	-8.50 [-17.74, 0.74]	
Riest 2008 (pre)	24.9	18.6	80	31.3	21.8	27	5.6%	-6.40 [-15.58, 2.78]	
Siribumrungwong 2015 Subtotal (95% CI)	14.8	8.1	32	14.9	9.3	32 172	8.0% 31.4%	-0.10 [-4.37, 4.17] -6.70 [-14.04, 0.63]	
Heterogeneity: $Tau^2 = 53$	96. Chi2	= 20 14	df = 4	(P = 0)	0005)	² = 80%	6		
Test for overall effect: Z =	1.79 (P	= 0.07	, a	(007			
	1.10 (1	0.01)							
1.9.2 THA									
Camu 2017	22.8	15.23	58	37.3	15.08	28	6.7%	-14.50 [-21.32, -7.68]	
Martinez 2007 (post)	25	13	22	47	27	10	2.7%	-22.00 [-39.59, -4.41]	
Martinez 2007 (pre)	26	12	20	47	27	11	2.9%	-21.00 [-37.80, -4.20]	· · · · · · · · · · · · · · · · · · ·
Xiao 2019	28.7	9.9	69	44.9	10.5	72	8.4%	-16.20 [-19.57, -12.83]	-
Subtotal (95% CI)			169			121	20.8%	-16.19 [-19.12, -13.26]	•
Heterogeneity: Tau ² = 0.0	0; Chi ² =	0.97, d	f = 3 (P	= 0.81); $I^2 = 0^{\circ}$	%			
Test for overall effect: Z =	10.83 (F	P < 0.00	001)						
1.9.3 TKA									
Hubbard 2003	31.38	2.23	67	43.52	2.43	63	9.0%	-12.14 [-12.94, -11.34]	
Zhu 2014	8.36	1.62	50	14.8	1.66	50	9.1%	-6.44 [-7.08, -5.80]	
Subtotal (95% CI)			117			113	18.1%	-9.28 [-14.87, -3.70]	
Heterogeneity: Tau ² = 16.	11; Chi ²	= 117.9	1, df =	1 (P < 0	.00001); l² = 9	9%		
Test for overall effect: Z =	3.26 (P	= 0.001)						
1 9 4 THA/TKA									
Ittichaikulthol 2010	10 73	3.2	40	37 5	6 87	40	8 7%	-26 77 [-20 12 -24 42]	-
Mu 2017	15.1	3.7	310	18	4.9	310	9.1%	-20.77 [-23.72, -24.42]	
Subtotal (95% CI)	10.1	0.7	350	10	4.5	350	17.8%	-14.81 [-38.20, 8.58]	
Heterogeneity: Tau ² = 284	1 11: Chi	² = 365	82. df =	= 1 (P <	0 0000	1): 2 =	100%		
Test for overall effect: Z =	1.24 (P	= 0.21)	on, a.	. (.		•,,, •			
		,							
1.9.5 Orthopaedic Surge	ry								
Diaz-Borjon 2017	25.91	29.32	142	35.45	32.05	139	6.6%	-9.54 [-16.73, -2.35]	
Koppert 2006	60.66	16.72	25	74.43	17.7	25	5.4%	-13.77 [-23.31, -4.23]	
Subtotal (95% CI)			167			164	12.0%	-11.07 [-16.81, -5.33]	•
Heterogeneity: Tau ² = 0.0	0; Chi² =	0.48, d	f = 1 (P	= 0.49	; l ² = 0 ⁶	%			
Test for overall effect: Z =	3.78 (P	= 0.000	2)						
T-1-1 (05% OD			4405			000	400.001	44 00 1 44 70 7 0 1	
l otal (95% CI)			1135			920	100.0%	-11.30 [-14.79, -7.81]	
Heterogeneity: $Tau^2 = 34$.	95; Chi ²	= 629.5	8, df =	14 (P <	0.0000	1); I ² =	98%		-20 -10 0 10 20
lest for overall effect: Z =	6.34 (P	< 0.000	01)	(5 0)					Favours Parecoxib Favours Control
lest for subaroup differen	ces: Chi	- = 9.42	at = 4	(P = 0.0)	$J51. I^2 =$	57.6%			

Fig. 6 Forest plot of postoperative morphine consumption over 24 h, comparing parecoxib and control groups

	Parecoxib	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events To	tal Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Apfelbaum 2008	95 1	17 122	124	50.7%	0.83 [0.75, 0.90]	=
Bian 2018	7	46 14	42	0.8%	0.46 [0.20, 1.02]	
Desjardins 2004	14	16 17	17	11.3%	0.88 [0.71, 1.08]	
Malan 2003	36	52 55	61	12.7%	0.77 [0.63, 0.94]	
Rasmussen 2002	31	36 37	37	24.5%	0.86 [0.75, 0.99]	
Total (95% CI)	2	67	281	100.0%	0.83 [0.77, 0.89]	•
Total events	183	245				
Heterogeneity: Tau ² = 0	0.00; Chi ² = 4	.34, df = 4 (F	= 0.36	5); l ² = 8%		
Test for overall effect: 2	Z = 5.04 (P <	0.00001)				Favours Parecoxib Favours Control

Fig. 7 Forest plot of the proportion of patients requiring rescue analgesia between the parecoxib and placebo groups

Incidence of Adverse Events

Pooled results from 11 RCTs [14, 15, 27–30, 39, 45–48] with 982 and 946 patients in the parecoxib and placebo groups, respectively, showed no significant difference in the incidence of adverse events (RR 0.95, 95%)

CI 0.86–1.04, P = 0.27, Fig. 8). All events were minor, including nausea and vomiting, head-ache and dizziness, pruritus or skin rash, and constipation. No gastrointestinal bleeding or cardiovascular events occurred.

 Δ Adis

	Pareco	xib	Control			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Apfelbaum 2008	27	117	42	124	5.3%	0.68 [0.45, 1.03]	
Bian 2018	14	46	13	42	2.3%	0.98 [0.52, 1.84]	
Camu 2017	26	72	19	38	4.6%	0.72 [0.46, 1.12]	
Desjardins 2004	9	16	11	17	2.9%	0.87 [0.50, 1.52]	
Diaz-Borjon 2017	83	142	78	139	22.2%	1.04 [0.85, 1.27]	
Essex 2018	12	58	22	58	2.5%	0.55 [0.30, 1.00]	
Hubbard 2003	47	67	43	63	17.2%	1.03 [0.82, 1.29]	
Malan 2003	49	64	55	70	27.2%	0.97 [0.81, 1.17]	
Mu 2017	36	310	38	310	5.0%	0.95 [0.62, 1.45]	
Peng 2018	18	48	17	46	3.3%	1.01 [0.60, 1.72]	
Rasmussen 2002	25	42	24	39	7.3%	0.97 [0.68, 1.38]	
Total (95% CI)		982		946	100.0%	0.95 [0.86, 1.04]	•
Total events	346		362				
Heterogeneity: Tau ² = 0	0.00; Chi ²	= 9.25	df = 10 (P = 0.5	i1); l² = 0%	~ —	
Test for overall effect: 2	z = 1.09 (I	P = 0.2	7)				U.3 U.7 I 1.5 Z

Fig. 8 Forest plot of AEs in the parecoxib group compared with the placebo group

Publication Bias of Included Studies

The analyses produced asymmetric funnel plots for postoperative 24 h morphine consumption, and Egger's test revealed no publication bias for the included studies (P = 0.253). The funnel plot for the incidence of adverse events was symmetrical, indicating no significant publication bias (Figs. 9, 10).

Studies Not Included in the Quantitative Synthesis

Ten trials [24, 25, 30, 32, 34–36, 43, 44, 48] compared parecoxib with other active therapies. Parecoxib was compared with ketorolac in three studies [25, 32, 48] and paracetamol in another three studies [34, 43, 44]. The results showed that parecoxib had comparable analgesic effects to those of ketorolac, which was not



Fig. 9 Funnel plots of postoperative morphine consumption over 24 h



Fig. 10 Funnel plots of the incidence of adverse events

significantly different from those of paracetamol. Other NSAIDs (diclofenac and celecoxib) were used in two studies [35, 36].

Sensitivity Analysis

Substantial heterogeneity, as demonstrated by $I^2 > 50\%$, occurred in most of primary outcomes. Sensitivity analyses were performed, showing robust results and revealing reduced heterogeneity for postoperative resting pain scores at 6, 12, and 24 h and postoperative movement pain scores at 6 h. However, heterogeneity remained high in other outcomes (see Table S4 in the electronic supplementary material for details).

GRADE Assessment

The GRADE assessment demonstrated an overall moderate level of evidence for each of the following outcomes: postoperative resting pain score at 6, 12, 24, and 48 h; postoperative movement pain score at 48 h; and proportion of patients requiring rescue analgesia. The level of evidence for the following outcomes was considered low: postoperative movement pain score at 6, 12, and 24 h and incidence of adverse events (see Table S5 in the electronic supplementary material for details).

DISCUSSION

The findings of this systematic review and metaanalysis demonstrated that parecoxib could relieve pain in most types of orthopedic surgery and spare cumulative morphine consumption without increasing the incidence of adverse events. The strength of this review over previous studies [11, 12, 49] was its focus on orthopedic surgeries and producing the evidence according to the most up-to-date RCTs available. Movement pain is more severe than resting pain [50, 51] and is significantly associated with a patient's ability to perform postoperative recovery activities. In our review, pain was differentiated depending on whether the patient was at rest or in movement, and the analgesic effect of parecoxib in various orthopedic procedures was evaluated at different timepoints. This study highlights that, for researchers, different orthopedic procedures and pain states may influence the outcome of analgesic drug assessments, and therefore this is a vital influence that needs to be taken into account in study design and clinical observations. Furthermore, this study facilitates a more comprehensive and objective understanding of parecoxib by orthopedic surgeons and patients and helps to improve the efficiency of decisionmaking in perioperative drug selection.

NSAIDs exert analgesic effects through multiple mechanisms in the postoperative period and have become an irreplaceable component of multimodal analgesia regimens. The primary effect of NSAIDs is COX inhibition [52]. COX-1 is considered to be involved in physiological functions, such as gastric protection and hemostasis [53], while COX-2 is linked to pathophysiologic processes, such as inflammation, pain, and fever [54]. As a selective COX-2 inhibitor, parecoxib provides analgesic effect by blocking the arachidonic acid cascade and production of prostaglandins [55, 56], reducing spinal prostaglandin release [57], and preventing peripheral and central sensitization while maintaining COX-1 physiological function with minimal side effects [58, 59]. In addition, parecoxib sodium is a water-soluble drug that can be rapidly hydrolyzed to valdecoxib after intravenous injection [10], has a long half-life, and can quickly penetrate the blood-brain barrier [60].

In terms of pain relief, the main measurement methods were the VAS and VNRS. Owing to the subjectivity of the pain measurements, this outcome may show high heterogeneity. Unlike previous studies [12, 49], when categorizing pain scores into resting and movement states, we discovered that parecoxib relieved postoperative resting pain but not postoperative movement pain at 6 and 12 h. Furthermore, we reckoned that the different timing, frequency, and duration of parecoxib administration in the included studies contributed to the differences in pain relief outcomes. However, it should not be overlooked that the mean differences in pain scores are very small and may not be clinically significant. Previous trials have also reached inconsistent conclusions regarding this issue. Some trials reported that parecoxib administration for 2 or 3 days reduced the postoperative pain scores both at rest and during movement [26, 33], whereas another trial found that preincisional administration of a single dose of parecoxib did not significantly reduce the postoperative VAS scores either at rest or during movement compared with placebo [15]. As a result, 2-3 days of administration provided better postoperative analgesia than a single parecoxib dose. Parecoxib use < 3 days for effective analgesia is also suggested in the drug prospect and considered to benefit patient recovery and avoid influencing platelet function as occurs during long-term use [58]. Additionally, the proportion of patients requiring rescue analgesia was significantly lower in the parecoxib group than in the placebo group in this review, similar to previous findings [11].

Although opioids remain the most commonly used analgesics for postoperative pain control, their use in clinical postoperative pain is limited by significant side effects such as nausea, vomiting [61], and even respiratory depression [62], as well as dose-dependent adverse events that reduce patient comfort and delay recovery. Therefore, multimodal analgesia regimens have been used to reduce the need for opioids in clinical practice. Our study found that parecoxib reduced cumulative morphine consumption over 24 h by approximately 11.30 mg. The results of the subgroup analysis showed that parecoxib reduced opioid analgesic consumption in both hip and knee replacements as well as in other orthopedic surgeries. The outcome of cumulative morphine consumption in 24 h was included in a total of 12 trials, 11 of which used morphine as a rescue analgesic and one of which used piritramide or tramadol. Although one trial used piritramide or tramadol, the authors converted it to a morphine equivalent dose in the outcome report. Therefore, we considered that the difference in morphine equivalents was not clinically relevant in this study. According to our parecoxib did not significantly findings, increase the adverse event risk. A pooled analysis of 28 RCTs and of > 10 years of retrospective safety data of parecoxib revealed infrequent gastrointestinal events and other prespecified safety events, highlighting its satisfactory safety and tolerance in patients with postoperative pain [63].

When assessing the certainty of findings using GRADE, we ranked certainty as ranging from low to moderate for efficacy and safety outcomes. "Low certainty" means that our confidence in the effect estimate is limited, and the true effect may be substantially different from the effect estimate. Some individual studies had an unclear risk of bias for issues such as allocation concealment and blinding, and a high risk of reporting bias. For the outcomes for which we were able to perform pooled analysis, we further downgraded the certainty of evidence owing to issues with imprecision or important inconsistency.

This study had several limitations. First, most of the included RCTs compared the treatments against placebo, which limited comparative effectiveness inferences. Therefore, further head-to-head trials of active therapies are warranted. Second, we combined orthopedic surgery of various types. The fact that different types of surgery are performed with varying degrees of intensity and characteristics may have an impact on the results' validity. Third, since baseline pain scores were missing in some included trials, we only extracted and synthesized endpoint pain score values. In addition, considering the differences in pain relief measurement (VAS or VNRS), drug selection and dosage, and timing of drug administration among studies, heterogeneity was unavoidable. We selected a random-effect model, instead of a fixed-effect model, to synthesize the outcome measures; however, the reliability of the related outcomes was evaluated using the GRADE approach.

To the best of our knowledge, whether parecoxib should be administered prior to surgery to provide preemptive analgesia has not been clarified. Further research is required to determine whether there are differences in analgesic effects between pre- and postoperative administration and single-dose and multiple administrations. In addition, more studies comparing parecoxib with other NSAIDs are required.

CONCLUSION

The certainty of the evidence for intravenous parecoxib as a treatment for orthopedic surgical pain varies in efficacy and safety outcomes, from low to moderate. The available evidence indicates that parecoxib might relieve postoperative orthopedic pain and reduce opioid analgesic consumption. Additional data comparing parecoxib with other NSAIDs in a perioperative setting are required to confirm the present findings.

ACKNOWLEDGEMENTS

Funding. This study and the Rapid Service Fee were funded by the authors.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. XL and PZ were the main author drafting the manuscript, reviewing all articles, extracting data, and conducting the statistical analyses for further analyses. HT helped with data interpretation, and assisted in drafting the manuscript. ZL contributed to the study design and coordination, helped with data interpretation, and assisted in drafting the manuscript. SZ was the main supervisor of the study design and coordination, reviewed all articles, conducted data extraction, interpreted data, and assisted in the manuscript drafting. All authors participated in the discussion and decision on the PICOs and the methodology of this systematic review. All authors contributed to and approved the protocol (CRD42021274939) as well as the final manuscript.

Disclosures. Xiaofei Li, Pengxiang Zhou, Zhengqian Li, Huilin Tange, and Suodi Zhai have nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Data Availability. This is a secondary study; hence all data used in this study are available in the literature.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, http://creativecommons.org/licenses/byvisit nc/4.0/.

REFERENCES

- 1. Treatment Guideline for Lumbar Spine Surgery. Washington State Department of Labor & Industries. 2021. https://www.lni.wa.gov/patient-care/ advisory-committees.
- 2. Joint replacement (primary): hip, knee and shoulder. NICE guideline. 2020. https://www.nice.org. uk/guidance/ng157.
- 3. Debono B, Wainwright TW, Wang MY, Sigmundsson FG, Yang MMH, Smid-Nanninga H, et al. Consensus statement for perioperative care in lumbar spinal fusion: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Spine J. 2021;21(5):729–52.
- 4. Jildeh TR, Abbas MJ, Hasan L, Moutzouros V, Okoroha KR. Multimodal nonopioid pain protocol provides better or equivalent pain control

compared to opioid analgesia following arthroscopic rotator cuff surgery: a prospective randomized controlled trial. Arthroscopy. 2022;38(4): 1077–85.

- Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152(7):691–7.
- 6. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–57.
- Acute pain management: scientific evidence (5th Edition). EvidenceUpdates. 2020. https://www. anzca.edu.au/news/top-news/acute-painmanagement-scientific-evidence-5th-edit.
- 8. Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;9:D8659.
- 9. Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013;10:D4233.
- 10. Cheer SM, Goa K. Parecoxib (parecoxib sodium). Drugs. 2001;61(8):1133-41 (1142-1143).
- 11. Lloyd R, Derry S, Moore RA, Mcquay HJ. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;2:D4771.
- 12. Du X, Gu J. The efficacy and safety of parecoxib for reducing pain and opioid consumption following total knee arthroplasty: a meta-analysis of randomized controlled trials. Int J Surg. 2018;59: 67–74.
- 13. Villasís-Keever MA, Rendón-Macías ME, Escamilla-Núñez A. Systematic review to assess the effectiveness and safety of parecoxib. Acta Ortop Mex. 2009;23(6):342–50.
- 14. Bian YY, Wang LC, Qian WW, et al. Role of parecoxib sodium in the multimodal analgesia after total knee arthroplasty: a randomized double-blinded controlled trial. Orthop Surg. 2018;10(4): 321–7.
- 15. Peng HM, Wang LC, Wang W, et al. Preemptive analgesia with parecoxib in total hip arthroplasty: a

785

randomized, double-blind, placebo-controlled trial. Pain Physician. 2018;21(5):483–8.

- Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.
- 17. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008.
- 18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.
- 19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
- 20. Dickersin K, Berlin JA. Meta-analysis: state-of-thescience. Epidemiol Rev. 1992;14:154–76.
- 21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and randomeffects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.
- 22. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
- 23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
- 24. Ma HH, Chou TFA, Wang HY, et al. An opioidsparing protocol with intravenous parecoxib can effectively reduce morphine consumption after simultaneous bilateral total knee arthroplasty. Sci Rep-UK. 2021;11(1):7362.
- 25. Laoruengthana A, Rattanaprichavej P, Reosanguanwong K, Chinwatanawongwan B, Chompoonutprapa P, Pongpirul K. A randomized controlled trial comparing the efficacies of ketorolac and parecoxib for early pain management after total knee arthroplasty. Knee. 2020;27(6):1708–14.
- 26. Xiao K, Yu L, Xiao W, et al. Pain management using perioperative administration of parecoxib for total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. Pain Physician. 2019;22(6): 575–82.
- 27. Essex MN, Choi HY, Brown PB, Cheung R. A randomized study of the efficacy and safety of parecoxib for the treatment of pain following total knee

arthroplasty in Korean patients. J Pain Res. 2018;11: 427–33.

- 28. Diaz-Borjon E, Torres-Gomez A, Essex MN, et al. Parecoxib provides analgesic and opioid-sparing effects following major orthopedic surgery: a subset analysis of a randomized, placebo-controlled clinical trial. Pain Therapy. 2017;6(1):61–72.
- 29. Mu DL, Zhang DZ, Wang DX, et al. Parecoxib supplementation to morphine analgesia decreases incidence of delirium in elderly patients after hip or knee replacement surgery: a randomized controlled trial. Anesth Analg. 2017;124(6):1992–2000.
- 30. Camu F, Borgeat A, Heylen RJ, Viel EJ, Boye ME, Cheung RY. Parecoxib, propacetamol, and their combination for analgesia after total hip arthroplasty: a randomized non-inferiority trial. Acta Anaesthesiol Scand. 2017;61(1):99–110.
- 31. Zhu YZ, Yao R, Zhang Z, Xu H, Wang LW. Parecoxib prevents early postoperative cognitive dysfunction in elderly patients undergoing total knee arthroplasty: a double-blind, randomized clinical consort study. Medicine (Baltimore). 2016;95(28): e4082.
- 32. Siribumrungwong K, Cheewakidakarn J, Tangtrakulwanich B, Nimmaanrat S. Comparing parecoxib and ketorolac as preemptive analgesia in patients undergoing posterior lumbar spinal fusion: a prospective randomized double-blinded placebocontrolled trial. BMC Musculoskelet Disord. 2015;16:59.
- 33. Zhu Y, Wang S, Wu H, Wu Y. Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study. Eur J Orthop Surg Traumatol. 2014;24(3):395–401.
- 34. Elseify ZA, El-Khattab SO, Khattab AM, Atta EM, Ajjoub LF. Combined parecoxib and I.V. paracetamol provides additional analgesic effect with better postoperative satisfaction in patients undergoing anterior cruciate ligament reconstruction. Saudi J Anaesth. 2011;5(1):45–9.
- 35. Paz-Estrada C, Vilaplana-Santalo CA, Perdomo-Gutiérrez RE. Preemptive analgesia with diclofenac and parecoxib in orthopedic surgery. Revista Mexicana de Anestesiologia. 2011;34(3):159–63.
- Ittichaikulthol W, Prachanpanich N, Kositchaiwat C, Intapan T. The post-operative analgesic efficacy of celecoxib compared with placebo and parecoxib after total hip or knee arthroplasty. J Med Assoc Thai. 2010;93(8):937–42.
- 37. Vadalouca A, Moka E, Chatzidimitriou A, Siafaka I, Sikioti P, Argyra E. A randomized, double-blind,

placebo-controlled study of preemptively administered intravenous parecoxib: effect on anxiety levels and procedural pain during epidural catheter placement for surgical operations or for chronic pain therapy. Pain Pract. 2009;9(3):181–94.

- 38. Jirarattanaphochai K, Thienthong S, Sriraj W, et al. Effect of parecoxib on postoperative pain after lumbar spine surgery: a bicenter, randomized, double-blinded, placebo-controlled trial. Spine (Phila Pa 1976). 2008;33(2):132–9.
- 39. Apfelbaum JL, Desjardins PJ, Brown MT, Verburg KM. Multiple-day efficacy of parecoxib sodium treatment in postoperative bunionectomy pain. Clin J Pain. 2008;24(9):784–92.
- 40. Riest G, Peters J, Weiss M, et al. Preventive effects of perioperative parecoxib on post-discectomy pain. Br J Anaesth. 2008;100(2):256–62.
- 41. Bláha M, Kukla R, Kozák J, Tichý M. Parecoxib in the treatment of postoperative pain after lumbar discectomy—a prospective randomized double blind trial. Bolest. 2007;10(3):156–9.
- 42. Martinez V, Belbachir A, Jaber A, et al. The influence of timing of administration on the analgesic efficacy of parecoxib in orthopedic surgery. Anesth Analg. 2007;104(6):1521–7.
- 43. Koppert W, Frotsch K, Huzurudin N, et al. The effects of paracetamol and parecoxib on kidney function in elderly patients undergoing orthopedic surgery. Anesth Analg. 2006;103(5):1170–6.
- 44. Grundmann U, Wörnle C, Biedler A, Kreuer S, Wrobel M, Wilhelm W. The efficacy of the nonopioid analgesics parecoxib, paracetamol and metamizol for postoperative pain relief after lumbar microdiscectomy. Anesth Analg. 2006;103(1): 217–22.
- 45. Desjardins PJ, Traylor L, Hubbard RC. Analgesic efficacy of preoperative parecoxib sodium in an orthopedic pain model. J Am Podiatr Med Assoc. 2004;94(3):305–14.
- 46. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth. 2003;90(2):166–72.
- 47. Malan TJ, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology. 2003;98(4): 950–6.
- 48. Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium for acute

pain after orthopedic knee surgery. Am J Orthop (Belle Mead NJ). 2002;31(6):336–43.

- 49. Zhang Z, Xu H, Zhang Y, et al. Nonsteroidal antiinflammatory drugs for postoperative pain control after lumbar spine surgery: a meta-analysis of randomized controlled trials. J Clin Anesth. 2017;43: 84–9.
- 50. Trost Z. All pain is not created equal: differentiating between pain during movement versus pain at rest following total knee arthroplasty. Pain. 2012;153(11):2161–2.
- 51. Rakel BA, Blodgett NP, Zimmerman BM, et al. Predictors of postoperative movement and resting pain following total knee replacement. Pain. 2012;153(11):2192–203.
- 52. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998; 104 (3A):2S-8S, 21S-22S.
- 53. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268(9):6610–4.
- 54. Dewitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med. 1993;95(2A):40S-44S.
- 55. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–42.
- Padi SS, Jain NK, Singh S, Kulkarni SK. Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol. 2004;491(1):69–76.
- 57. Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. Neurosci. 2001;21(16):5847–53.
- 58. Teerawattananon C, Tantayakom P, Suwanawiboon B, Katchamart W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):520–8.
- 59. Schug SA, Joshi GP, Camu F, Pan S, Cheung R. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesth Analg. 2009;108(1):299–307.

- 60. Mehta V, Johnston A, Cheung R, Bello A, Langford RM. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther. 2008;83(3):430–5.
- 61. Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1): 85–113.
- 62. Algera MH, Kamp J, Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaesth. 2019;122(6):e168–79.
- 63. Schug SA, Parsons B, Li C, Xia F. The safety profile of parecoxib for the treatment of postoperative pain: a pooled analysis of 28 randomized, doubleblind, placebo-controlled clinical trials and a review of over 10 years of postauthorization data. J Pain Res. 2017;10:2451–9.